2023 Approvals

A Groundbreaking Approval: FDA Greenlights Truqap for Advanced Breast Cancer

A Groundbreaking Approval: FDA Greenlights Truqap for Advanced Breast Cancer

What is Truqap prescribed for?  Truquap is perscribed in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following...

Zepbound Injection Approved for Weight Loss in Overweight and Obese Adults on November 8, 2023

Zepbound Injection Approved for Weight Loss in Overweight and Obese Adults on November 8, 2023

What is Zepbound prescribed for?   Zepbound is prescribed for Chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in...

Brixadi Approved  for Treatment of Opioid Use Disorder on May 05, 2023

Brixadi Approved  for Treatment of Opioid Use Disorder on May 05, 2023

What is Brixadi prescribed for? Brixadi is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.  What is the name of the drug and what does it do? Brixadi, pronounced brix-a-dee, (generic name:...

Zilbrysq: FDA-Approved on October 17, 2023, for Treating Generalized Myasthenia Gravis

Zilbrysq: FDA-Approved on October 17, 2023, for Treating Generalized Myasthenia Gravis

What is Zilbrysq prescribed for?   Zilbrysq is prescribed to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. What is the name of the drug and what does it do?  Zilbrysq, pronounced ZIL-brisk, (generic name: zilucoplan) is  for generalized myasthenia gravis (MG) treatment in adults. ...

FDA Approval on February 16, 2023: LAMZEDE Breakthrough for Alpha-Mannosidosis Treatment

FDA Approval on February 16, 2023: LAMZEDE Breakthrough for Alpha-Mannosidosis Treatment

What is LAMZEDE prescribed for?    For the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. What is the name of the drug and what does it do?  LAMZEDE (generic name: velmanase alfa-tycv), pronouonced “lam-zed,” is a medicine made from human genes that helps treat the non-brain...

A New Era in Lung Cancer Treatment: FDA Approves Augtyro on November 15, 2023

A New Era in Lung Cancer Treatment: FDA Approves Augtyro on November 15, 2023

What is Augtyro prescribed for?  Augtyro is prescribed for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. What is Augtyro and what does it do? Augtyro, pronounced Aug-TYE-ro, (generic name: repotrectinib) is a newly FDA-approved medication for treating a specific type of lung cancer called...